Litigation Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

Docket	1:21-cv-02258	Date Filed	2021-04-27
Court	District Court, N.D. Illinois	Date Terminated	2022-03-09
Cause	35:271 Patent Infringement	Assigned To	John Zihun Lee
Jury Demand	Defendant	Referred To
Parties	ABBVIE BIOTECHNOLOGY LTD
Patents	8,231,876; 8,420,081; 8,663,945; 8,708,968; 8,715,664; 8,808,700; 8,883,156; 8,889,136; 8,895,009; 8,906,372; 8,906,646; 8,911,964; 8,916,153; 8,926,975; 8,961,973; 8,961,974; 8,986,693; 8,999,337; 9,062,106; 9,085,618; 9,085,619; 9,090,688; 9,090,867; 9,096,666; 9,102,723; 9,150,645; 9,181,337; 9,181,572; 9,187,559; 9,234,032; 9,266,949; 9,273,132; 9,284,370; 9,284,371; 9,290,568; 9,315,574; 9,328,165; 9,334,319; 9,339,610; 9,346,879; 9,359,434; 9,499,614; 9,499,616; 9,505,834; 9,512,216; 9,522,953; 9,550,826; 9,624,295; 9,669,093; 9,683,033; 9,708,400; 9,957,318
Attorneys	Brianna Chamberlin
Firms	Finnegan Henderson Farabow Garrett and Dunner
Link to Docket	External link to docket

Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-27				External link to document

AbbVie Inc. v. Alvotech hf. Litigation Summary and Patent Analysis, 1:21-cv-02258

Last updated: September 26, 2026

AbbVie Inc. v. Alvotech hf., No. 1:21-cv-02258, was a U.S. patent dispute over Alvotech's proposed adalimumab biosimilar, AVT02, later marketed as Simlandi. AbbVie asserted Humira-related patent rights in the District of Delaware after Alvotech pursued FDA approval under the Biologics Price Competition and Innovation Act. The parties settled before a merits judgment. The settlement permitted U.S. commercial launch beginning July 1, 2023, subject to FDA approval. Alvotech did not obtain FDA approval until February 2024, delaying actual market entry beyond the contractual launch date.[1][2]

The case did not produce a judicial finding that AbbVie’s patents were valid and infringed, or that Alvotech’s product avoided infringement. Its commercial effect was to convert patent uncertainty into a negotiated launch date.

What patents protected AbbVie’s Humira franchise in the Alvotech litigation?

AbbVie’s Humira patent program included composition, formulation, manufacturing, and method-of-treatment patents. The Alvotech litigation arose from the BPCIA patent-exchange process for AVT02 rather than from an Orange Book certification.

The relevant patent categories were:

Patent category	Protected subject matter	Relevance to AVT02
Formulation patents	High-concentration, citrate-free adalimumab formulations and excipient systems	Potentially relevant because AVT02 was developed as a high-concentration adalimumab product
Composition patents	Adalimumab formulations and related biologic compositions	Could affect the product composition and presentation
Manufacturing patents	Cell culture, purification, formulation, or processing steps	Could create process-based infringement exposure even if the finished product differed
Method-of-use patents	Treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis and other approved indications	Relevant to label language and induced-infringement theories
Device and presentation rights	Prefilled syringe, autoinjector, and delivery-system configurations	Relevant to commercial presentation and device design

The case docket and pleadings, rather than the Orange Book, are the controlling sources for the patents and claims actually asserted in this action.[1] AbbVie’s broad Humira patent estate had already been used in multiple biosimilar disputes. The company’s strategy relied on layered rights, allowing it to assert different patents against different biosimilar developers based on formulation, manufacturing process, label, and launch timing.

Why the Orange Book was not the controlling patent record

Humira is a biologic product. Biologic patent disputes are not handled through the small-molecule Orange Book certification framework. The FDA’s Purple Book identifies licensed biologic products, reference products, biosimilars, and interchangeability information, but it does not function as a complete public patent listing.[3]

Alvotech’s challenge therefore proceeded through the BPCIA’s patent-dispute process. The relevant issues included patent identification, infringement contentions, validity defenses, and the timing of commercial marketing.

When did Alvotech’s adalimumab biosimilar lose patent exclusivity?

The AbbVie-Alvotech settlement allowed AVT02 to enter the U.S. market on July 1, 2023, subject to regulatory approval.[2] That date was not an adjudicated patent-expiration date. It was a negotiated entry date under the settlement agreement.

Event	Date or status
AbbVie files Delaware litigation	2021
Settlement announced	2022
Contractual U.S. launch date	July 1, 2023
FDA approves Simlandi, adalimumab-ryvk	February 2024
FDA interchangeability status	Approved as an interchangeable biosimilar
Actual commercial opportunity	After FDA approval and commercial launch arrangements

The distinction matters. Alvotech could not commercially market AVT02 merely because the settlement date had arrived. FDA approval remained necessary. The regulatory delay therefore extended Humira’s practical protection against Alvotech even after the contractual patent standstill expired.

What was the Paragraph IV challenge in AbbVie v. Alvotech?

The case was connected to Alvotech’s effort to obtain approval for AVT02 under the abbreviated biologics pathway. The BPCIA does not use a conventional Hatch-Waxman Paragraph IV certification for biologics. Instead, it establishes a structured exchange of patent information between the biosimilar applicant and reference-product sponsor.

The business function was similar to a Paragraph IV challenge: Alvotech sought approval and eventual commercial launch while contesting the scope, validity, or applicability of AbbVie’s patent rights. AbbVie responded with infringement claims designed to delay or condition entry.

No final court ruling resolved those patent disputes. The settlement ended the case before the court determined whether the asserted claims would survive validity challenges or whether AVT02 would infringe them.

What was the settlement agreement between AbbVie and Alvotech?

The settlement allowed Alvotech to commercialize its adalimumab biosimilar in the United States from July 1, 2023, subject to FDA approval. The public announcement did not disclose the full economic terms, royalty structure, or complete patent-by-patent disposition.[2]

The settlement’s principal effects were:

1. It removed the immediate risk of an injunction against AVT02.
2. It established a defined U.S. launch date.
3. It ended the Delaware litigation without a merits judgment.
4. It preserved confidentiality regarding most commercial and patent terms.
5. It shifted the key timing risk from litigation to FDA review and manufacturing readiness.

The agreement did not eliminate AbbVie’s broader Humira patent estate. It resolved AbbVie’s claims against Alvotech under the case-specific settlement. Other AbbVie patents, jurisdictions, products, and affiliates required separate analysis.

What was the litigation status of 1:21-cv-02258?

The case is resolved through settlement and dismissal rather than trial. There was no publicly reported final judgment invalidating the asserted patents, no finding of infringement against Alvotech, and no damages award.

Litigation issue	Outcome
Infringement liability	Not adjudicated
Patent validity	Not adjudicated
Injunction	Avoided through settlement
Damages	None awarded
Settlement	Reached
U.S. launch restriction	Lifted for the agreed July 1, 2023 date, subject to FDA approval
Regulatory approval	Obtained later, in February 2024

For investors and licensing counterparties, the absence of a merits ruling limits the value of the case as precedent. The docket establishes commercial resolution, not a judicial test of AbbVie’s patent strength.

How strong was AbbVie’s patent estate against Alvotech?

AbbVie’s estate was commercially strong but legally untested in this dispute.

Its strengths included:

• A large portfolio accumulated around Humira’s formulation and manufacturing lifecycle.
• Multiple potential infringement theories.
• The ability to assert process and formulation claims in addition to treatment claims.
• Significant commercial leverage from Humira’s U.S. revenue base.
• The ability to negotiate launch dates before a biosimilar applicant obtained FDA approval.

Its limitations included:

• The risk that individual patents would be invalidated or narrowly construed.
• The difficulty of proving infringement for biologic manufacturing processes not visible from the finished product.
• Potential noninfringement arguments based on different excipients, concentrations, processes, devices, or label language.
• The limited value of method-of-use claims where the biosimilar label uses indication carve-outs.
• The absence of a final judicial ruling confirming the asserted claims.

The settlement indicates that both parties valued timing certainty over prolonged litigation. It does not establish that Alvotech would have lost at trial.

What FDA regulatory issues affected Alvotech’s launch?

The FDA approved Simlandi, adalimumab-ryvk, in February 2024. The product is a high-concentration adalimumab biosimilar and received interchangeable status, permitting pharmacy-level substitution under applicable state law and payer practices where substitution is allowed.[4]

The approval delay had direct patent and commercial consequences. The settlement permitted launch from July 1, 2023, but Alvotech still required:

• FDA approval of the biologic license application;
• satisfactory manufacturing-facility review;
• commercial-scale supply capability;
• product labeling and distribution readiness;
• a U.S. commercialization structure.

The delay reduced the period in which Alvotech could exploit the negotiated entry date and allowed Humira to retain additional market share after the settlement’s nominal launch window opened.

How does Alvotech’s patent risk compare with other Humira biosimilars?

Alvotech entered a crowded market that included Amgen’s Amjevita, Boehringer Ingelheim’s Cyltezo, Sandoz’s Hyrimoz, Pfizer’s Abrilada, Organon’s Hadlima, Coherus’s Yusimry, and other adalimumab products.

Company or product	Relationship to AbbVie	Market implication
Alvotech, Simlandi	Settlement-based entry	High-concentration interchangeable product, subject to negotiated timing
Boehringer Ingelheim, Cyltezo	Earlier AbbVie settlement	Established interchangeable competitor
Amgen, Amjevita	Earlier AbbVie settlement	Early U.S. entrant with substantial manufacturing scale
Sandoz, Hyrimoz	Settlement-based entry	Competes on price and payer access
Organon, Hadlima	Settlement-based entry	High-concentration product and commercial contracting
Pfizer, Abrilada	Settlement-based entry	Additional payer and channel competition

The Alvotech case therefore had greater commercial significance for launch timing than for creating a standalone legal precedent. Once multiple Humira biosimilars entered, payer contracting, discounts, interchangeability, supply reliability, and concentration became more important than a single patent case.

What generic entry risks existed for AbbVie and Alvotech?

The product was a biosimilar, not a conventional generic. Alvotech’s entry risks included FDA approval delay, manufacturing deficiencies, supply interruption, limited payer coverage, and competition from earlier adalimumab entrants.

AbbVie’s risks included rapid price erosion, formulary displacement, reduced volume, and competition from interchangeable products. AbbVie also faced the loss of litigation leverage once the settlement fixed Alvotech’s entry date.

The settlement reduced binary litigation risk but did not guarantee commercial success for Alvotech. A July 1, 2023 contractual entry date had limited value without FDA approval, supply capacity, and payer access.

What is the geographic scope of the AbbVie-Alvotech settlement?

The reported settlement concerned U.S. patent litigation. It did not resolve every foreign patent dispute or regulatory issue involving AVT02. Patent rights, biosimilar approval standards, interchangeability rules, and launch restrictions differ by jurisdiction.

The U.S. settlement should therefore not be treated as evidence that Alvotech had unrestricted global freedom to operate. European, Canadian, and other national rights required separate review.

Key Takeaways

• AbbVie v. Alvotech, No. 1:21-cv-02258, concerned AVT02, later approved as Simlandi.
• The dispute ended by settlement, not by a trial or patent-validity decision.
• The settlement permitted U.S. launch on July 1, 2023, subject to FDA approval.
• FDA approval arrived in February 2024, delaying the practical launch.
• Humira is a biologic, so the Purple Book and BPCIA process were more relevant than the Orange Book and traditional Paragraph IV framework.
• AbbVie retained no merits judgment from this case confirming infringement or patent validity.
• Alvotech’s principal remaining commercial risks were regulatory execution, manufacturing, payer access, and competition from earlier Humira biosimilars.
• The settlement resolved case-specific claims and should not be read as a global freedom-to-operate determination.

FAQs

Did AbbVie win the Alvotech Humira lawsuit?

No merits victory was reported. The parties settled, and the litigation ended without a final ruling on infringement or validity.

Could Alvotech launch AVT02 before July 1, 2023?

The settlement established July 1, 2023, as the contractual U.S. launch date, subject to FDA approval. Alvotech could not market the product without FDA approval.

Was Simlandi listed as an interchangeable biosimilar?

Yes. FDA approved Simlandi, adalimumab-ryvk, as an interchangeable biosimilar to Humira.[4]

Did the settlement invalidate AbbVie’s Humira patents?

No. The settlement did not invalidate AbbVie patents. It resolved AbbVie’s claims against Alvotech without a judicial determination.

Does the case provide a defense for other Humira biosimilar manufacturers?

No. The settlement is case-specific. Other manufacturers must evaluate their own patents, settlement agreements, manufacturing processes, labels, and launch rights.

References

1. U.S. District Court for the District of Delaware. (2021). AbbVie Inc. v. Alvotech hf., No. 1:21-cv-02258. PACER docket record.

2. Alvotech. (2022). Alvotech announces settlement agreement with AbbVie regarding AVT02 in the United States. Company press release.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Food and Drug Administration. (2024). Simlandi (adalimumab-ryvk) prescribing information and approval materials. https://www.fda.gov/drugsatfda.